A new year can bring feelings of uncertainty, especially in these difficult times. The last couple of years have been tough on all of us, and it’s normal to be experiencing a range of different emotions right now. If you’re struggling, remember you’re not alone. Here we share some tips and resources to help you take care of your wellbeing.
Amid the excitement surrounding the announcement that 6 to 11 year olds in the UK will be able to access the modulator drug Kaftrio, we know that for the many in our community who don’t benefit, the future will still feel uncertain. We won’t stop until everybody with CF can access the treatments they need. Here, our Director of Research Dr Lucy Allen, tells us about some of the exciting research that’s underway that could help those who don’t benefit from CFTR modulators.
Following the exciting announcement that the life-changing CF drug, Kaftrio, has been approved for use across the UK for 6 to 11 year olds, we caught up with Stacey, whose eight-year-old daughter Katy has CF, to find out about the difference this could make to Katy’s future.
Following the announcement that Kaftrio has been approved for use for eligible children aged 6-11 in Northern Ireland, we are delighted that the MHRA has also now approved the life-changing CF drug for children across the rest of the UK too. This is a huge milestone in the Kaftrio journey following years of campaigning by people with cystic fibrosis and their families.
The life-changing cystic fibrosis drug, Kaftrio, has been approved for use for eligible children aged 6-11 in Northern Ireland. This is a huge milestone in the Kaftrio journey following years of campaigning by people with cystic fibrosis and their families.
A group of charities, including the Trust, have published a letter for everyone who is at highest risk from COVID-19 to download and use in discussion with your employers about how to keep safe at work.
Dr Mike Gray's Strategic Research Centre is working to understand more about alternative drug targets to CFTR to develop disease modifying treatments for cystic fibrosis.